HER2-mutated lung cancer: restarting targeted therapy after lung inflammation

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HER2 exon 20 insertion; PD-L1 negative

Metastatic Site: brain

Trastuzumab deruxtecan was restarted successfully after lung inflammation improved, but it was discontinued after 9 cycles when the cancer progressed.

PubMed CentralRead more →

Stage IV lung cancer presenting with a paraneoplastic neurologic syndrome and mixed tumor features

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: PD-L1 0%

Metastatic Site: bone (T10 and L5 vertebrae)

He died after rapid deterioration with severe encephalopathy, weakness and respiratory distress; advanced metastatic lung cancer with progressive paraneoplastic neurologic involvement was considered the most likely cause.

PubMed CentralRead more →

Stable lung cancer after recovery from a severe immunotherapy complication

Patient Info: Anonymized, Male, 60s

At 8-month follow-up, the primary lung tumor remained radiologically stable on maintenance chemotherapy without evidence of progression.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Rosee's Patient Story

Patient Info: Rosee, Female | Stage IV

Biomarkers: EGFR mutation; specific variant not reported

Metastatic Site: brain

Within weeks of starting osimertinib, Rosee’s tumors shrank significantly, migraines and vertigo resolved, and hearing began to return; she remained on treatment and active in advocacy.

Lung Cancer Research FoundationRead more →

Rosee

Patient Info: Anonymized, Male | Stage I

Biomarkers: Elevated carcinoembryonic antigen at detection; tumor biomarkers not reported

Lung Cancer Research FoundationRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: clonal evolution, chemoimmunotherapy response, osimertinib rechallenge, and death after progression

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Markers changed over time: started with EGFR L747S/L858R; later MET-amplified, PD-L1 TPS 80%, high TMB clone; later EGFR reappeared.

Metastatic Site: pleura, peritoneal nodule, retroperitoneal lymph nodes

The patient died on 30 April 2025 after progression through multiple lines and infection related to treatment-associated myelosuppression.

PubMed CentralRead more →

Metastatic lung cancer discovered after fluid built up around the heart

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: pericardium

She died after hospital-acquired pneumonia progressed to septic shock, before cancer-directed treatment could begin.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Shannon's Survivor Story

Patient Info: Shannon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: cervical spine (C1/C2 and C4/C6), liver

As of June 2026, Shannon described no evidence of active disease: visible tumors were gone, the original lung mass had decreased from 10.8 cm to a 3.8 cm cavity, and targeted therapy continued to suppress possible remaining cells.

The Patient StoryRead more →

Long-term complete response to targeted therapy for relapsed lung cancer with an EGFR mutation

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: EGFR mutation

Her three most recent scans showed a complete response, and nearly 4 years after relapse she remained free of tumor progression while continuing targeted therapy.

PubMed CentralRead more →

Extensive-stage small cell lung cancer: multi-line treatment complicated by glucocorticoid-refractory immune-related cystitis

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported for SCLC. Bladder biopsy during cystitis showed mostly CD3/CD8-positive T-cell inflammation.

As of December 2025, the cancer had progressed through multiple systemic lines, new brain metastasis had appeared, and care had shifted to palliative symptomatic treatment; immune-related cystitis had resolved after prednisone plus mycophenolate mofetil.

PubMed CentralRead more →

Stage IV PD-L1-high lung adenocarcinoma: remission on chemotherapy after tislelizumab-associated KLHL11-IgG cerebellitis

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-high lung adenocarcinoma with EGFR/ALK/ROS1 wild type and TTF-1 positive. KLHL11-IgG was linked to cerebellitis.

Metastatic Site: M1a disease; specific metastatic site not otherwise…

At 1-year neurologic follow-up, the cerebellitis had markedly improved, serum KLHL11-IgG was negative, brain MRI lesions had resolved, and lung adenocarcinoma remained in remission on cisplatin plus pemetrexed.

PubMed CentralRead more →

Stage IV EGFR-mutated lung adenocarcinoma: high-dose furmonertinib after CNS progression

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR L858R mutation. Later blood testing showed EGFR p.S553Y variation; CEA rose and fell with treatment.

Metastatic Site: brain/meninges; bilateral pleura/lungs; mediastinal…

As of June-September 2024, the left lung lesion was stable to slightly smaller on escalated furmonertinib, but brain/CNS lesions had progressed and required dose escalation to 240 mg/day; later imaging was declined.

PubMed CentralRead more →

Small Cell Lung Cancer: Montessa's Survivor Story

Patient Info: Montessa, Female, Under 40

As of June 2026, Montessa was sharing her recovery after limited-stage small cell lung cancer treatment with concurrent chemotherapy and radiation followed by brain radiation.

The Patient StoryRead more →

Stage IVA lung squamous cell carcinoma with immune-checkpoint-inhibitor-associated Graves thyroid storm

Patient Info: Anonymized, Male | Stage IV

Biomarkers: Cancer biomarkers not reported. Thyroid storm workup had TSAb/TRAb positivity consistent with Graves disease.

Metastatic Site: not specified in extracted case text

After thyroid storm improved with antithyroid therapy and supportive care, the patient was transferred for further lung-cancer treatment but died of progressive lung cancer about 2 months later.

PubMed CentralRead more →

Stage III Non-Small Cell Lung Cancer: Heidi's Survivor Story

Patient Info: Heidi N., Female, 50s | Stage III

Biomarkers: No targetable mutation identified

As of June 2026, Heidi was featured as a lung cancer advocate after treatment for inoperable Stage IIIA NSCLC; scans through January 2021 had shown no evidence of disease.

The Patient StoryRead more →

Stage III Lung Cancer: Bonnie's Patient Story

Patient Info: Bonnie Ulrich, Female, 40s | Stage III

Biomarkers: CA-125 elevated during 2019 workup; no lung cancer driver biomarker reported

After surgery-only Stage I lung cancer and 13 years in remission, Bonnie was later diagnosed with Stage III lung cancer in 2019; the later treatment regimen is not reported.

The Patient StoryRead more →

Pierre Onda: The Caregiver & His Fight for Empathy

Patient Info: Heidi Onda, Female | Stage III

Heidi Onda was diagnosed with Stage III primary lung cancer, and the story focuses on Pierre Onda's caregiver experience and their creation of The White Ribbon Project rather than a detailed treatment course or final disease status.

The Patient StoryRead more →

Lung cancer remains stable after pembrolizumab-related muscle inflammation

Patient Info: Anonymized, Female, 70+

She regained full mobility and independence, and her lung cancer remained stable on imaging in December 2025.

PubMed CentralRead more →

Keasha Rutledge: Stage IV Lung Cancer

Patient Info: Keasha Rutledge, Female, Under 40 | Stage IV

Metastatic Site: Not reported

Keasha Rutledge was diagnosed with Stage IV lung cancer at age 37, married Chris Draft 11 months later, and passed away 1 month after their wedding.

The Patient StoryRead more →

Recurrent squamous lung cancer with tumor emboli, acute limb ischemia, brain metastases, and death

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: p40-positive; TTF-1-negative; PD-L1 not expressed / no PD-L1 reported in raw case

Metastatic Site: brain/cerebral metastases; tumor emboli in upper and…

The patient developed recurrent acute limb ischemia from tumor emboli, then new cerebral metastases, and died from advanced disease 7 months after the bilateral lower-limb ischemia presentation.

PubMed CentralRead more →

Stage IV ALK Lung Cancer: Nancee's Patient Story

Patient Info: Nancee Pronsati, Female | Stage IV

Biomarkers: ALK-positive; ALK fusion/rearrangement

Metastatic Site: bilateral lung nodules, brain

As of May 2026, Nancee had lived about 10 years with metastatic ALK-positive lung cancer, including brain progression, and continued long-term targeted therapy with quality of life as a major goal.

The Patient StoryRead more →

Stage III Lung Cancer: Peter's Survivor Story

Patient Info: Peter, Male, 70+ | Stage III

As of May 2026, Peter said his left-lung mass had gone after radiotherapy with chemotherapy and that he had returned to normal activities.

YouTube (AR search)Read more →

Stage IV Non-Small Cell Lung Cancer: Jill's Patient Story

Patient Info: Jill, Female, 50s | Stage IV

Biomarkers: Driver mutation identified; specific mutation not stated

Metastatic Site: pleura

As of May 2026, Jill had lived 17 years with NSCLC, later experienced pleural metastases/progression, and remained on biomarker-guided targeted therapy with chemotherapy added.

The Patient StoryRead more →

EGFR-mutated lung cancer responds after acquired ROS1 resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; acquired ROS1 rearrangement

Metastatic Site: pleura

She remained on osimertinib plus crizotinib with a sustained clinical and radiologic response for more than 18 months.

PubMed CentralRead more →